New imaging agent could sharpen liver cancer detection

NCT ID NCT07677774

Recruiting now Diagnosis Sponsor: The First Affiliated Hospital of Xiamen University Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a new radioactive tracer called 68Ga-GPC3 that targets a protein found on liver cancer cells. About 40 adults with suspected or confirmed hepatocellular carcinoma will receive both this new tracer and a standard tracer (18F-FDG) for PET/CT scans. Researchers will compare how well each method spots tumors, aiming to improve diagnostic accuracy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-GPC3 (a radioactive tracer for PET imaging)
What this could lead to: If successful, this could provide a more accurate way to detect and monitor liver cancer, improving diagnosis and treatment planning.
What could go wrong: This is an early-stage study with only 40 participants, so results may not apply to all patients. The new tracer may not prove better than existing methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLYPICAN-3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Simpson-Golabi-Behmel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLYPICAN-3 GPC3-TARGETED PET/CT HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

The First Affiliated Hospital of Xiamen University
RECRUITING

Xiamen, Fujian, 361000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.